

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A process for the preparation of a composite containing a drug dispersed in an organic carrier, wherein the drug is massively dispersed (in bulk) within the particles of said organic carrier and it is present in amorphous form in a quantity greater than or equal to 50%, comprising the following steps:
 - a) forming a mixture of a drug with an organic carrier selected from the group consisting of water-soluble complexing agents chosen from cyclodextrins and maltodextrins, water-insoluble cross-linked polymers and mixtures thereof;
 - b) irradiating the mixture obtained in a), with microwaves, wherein the microwave power is modulated so that the temperature of the mixture increases until it reaches a value higher than the melting temperature of the drug and it is then maintained constant at said value for at least 5 minutes.
2. (Previously Presented) Process according to claim 1, wherein in step a) a wet mixture is formed by adding a solvent.
3. (Previously Presented) Process according to claim 2, wherein said solvent is water.
4. (Previously Presented) The process according to claim 3, in which said wet mixture is formed by adding water to the carrier-drug composite in a quantity comprised of between 0.1 ml/g and 5 ml/g with respect to the dry mixture of the composite.
5. (Currently Amended) The process according to ~~claims 2 to 4~~ claim 2, in which the pressure at which the irradiation is carried out is comprised of between 1 and 20 bar.

Page 3

6. (Currently Amended) A process according to ~~claims 1 to 4~~ claim 1, wherein step b) is carried out in a container constituted of a dielectric material having coupling capacity with the microwaves.
7. (Previously Presented) The process according to claim 6, wherein said dielectric material is polytetrafluoroethylene loaded with graphite.
8. (Currently Amended) The process according to ~~claims 1 to 7~~ claim 1, in which the irradiation with microwaves is carried out in ~~an~~ a power range comprised of between 100 W and 5000 W, for an overall time up to 120 minutes.
9. (Currently Amended) A process according to ~~claims 1 to 8~~ claim 1 wherein said cross-linked polymer is selected ~~from~~ from the group consisting of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene and cross-linked β -cyclodextrin.
10. (Currently Amended) A process according to ~~claims 1 to 9~~ claim 1 wherein said drug is a drug sparingly soluble in water.
11. (Previously Presented) A composite containing a drug dispersed in carrier consisting of a water soluble complexing agent selected from cyclodextrins and maltodextrins, wherein the drug is massively dispersed (in-bulk) within the particles of said complexing agent and it is present in amorphous form in a quantity greater than or equal to 50 % by weight, with respect to the total of drug present in the composite.
12. (Currently Amended) A composite according to claim ~~10~~ 11, wherein said cyclodextrins are selected from alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and derivatives thereof.

Page 4

13. (Currently Amended) A composite according to ~~claims 11 or 12~~ claim 11, wherein the drug and the carrier are present in weight ratios comprised of between 1:0.5 and 1:20.
14. (Previously Presented) A composite according to claim 13, wherein the drug and the carrier are present in weight ratios comprised of between 1:1 and 1:10.
15. (Currently Amended) A composite according to ~~claims 11 to 14~~ claim 11, wherein said carrier has a surface area comprised of between 0.05 m²/g and 20 m²/g.
16. (Currently Amended) A composite according to ~~claims 11 to 15~~ claim 11, wherein said drug is a drug sparingly soluble in water.
17. (Currently Amended) A composite according to claim 16, wherein said drug is selected from the group consisting of nimesulide, ibuprofen, nifedipine, grisofulvine, piroxicam, progesterone, lorazepam and mixtures thereof.
18. (Currently Amended) A composite as claimed in ~~claims 11 to 17~~ claim 11, for use in therapy.
19. (Currently Amended) A pharmaceutical composition containing a composite as claimed in ~~claims 11 to 18~~ claim 11, optionally associated with pharmaceutically acceptable excipients.
20. (Previously Presented) A pharmaceutical composition according to claim 19, formulated as a granulate, pill, mini-pill, capsule, micro-capsule.